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Abstract
Purpose. The incidence and treatment results of extremity soft tissue sarcoma (STS) in the Mersey Region, in the absence
of a Multi-Disciplinary Unit, for the period 1975± 1985, have been analysed.
Subjects and methods. Data from cases presenting with STS within the Mersey region, from 1 January 1975 until 31
December 1985, were reviewed. Only patients with sarcoma of head and neck, thoracic wall, abdominal wall, retroperi-
toneum, limb girdle or extremity were included. Extremity lesions were staged according to the MTS system. Pathological
data also were assigned a grade according to tumour differentiation, mitosis count and tumour necrosis. Data from
patients with a minimum follow-up of 5 years were collated, and patterns of treatment failure were investigated. Finally,
time to ® rst occurrence was analysed.
Results and Discussion. The incidence of STS in this study was identical to that reported by the US Department of Health
in 1976. Five year survival rate for Stage I tumours was only 51.7% which compares very unfavourably with contemporary
series from Multi-Disciplinary Units. Five year survival rate following wide local excision 6 adjuvant therapy is 52.4%,
while that following amputation6 adjuvant therapy is 45.5%. While not attaining the results reported by other centres,
limb-sparing surgery does not appear to appreciably prejudice long-term survival.
Conclusions. STS are rare in the UK, leading to poor classi® cation and suboptimal treatment of lesions. It is important
to establish multidisciplinary teams of surgeons, radiologists, radiotherapists and oncologists to plan and organise
multimodality therapy for STS.
Introduction
Soft Tissue Sarcomas (STS) are rare tumours, ac-
counting for less than 1% of malignant neoplasms.
1
Despite their rarity, recent advances in limb-sparing
techniques and the use of adjuvant radiotherapy and
chemotherapy
2 in multidisciplinary units
3,4 has seen
an improvement in their management. In the
Mersey Region between 1975 and 1985 no such
specialist unit existed. In this analysis, the incidence
and treatment results of extremity soft tissue sarco-
mas occurring in Mersey between 1975 and 1985
were investigated.
Subjects and methods
The Mersey Region Cancer Registry database was
utilised for this study. The case records of patients
presenting with soft tissue sarcomas within the
Mersey Region were reviewed from 1 January 1975
to 31 December 1985, inclusive. For eligibility,
patients required a histologically proven diagnosis of
sarcoma arising from the head and neck, thoracic
wall, abdominal wall, retroperitoneum, limb girdle
or extremity. Visceral sarcomas and metastatic sar-
comas of unknown primary were excluded. The
eligible patient population was then examined to
derive age/sex distribution and age-speci® c annual
incidence. Patients with limb girdle and extremity
STS were further examined to calculate their age/
sex distribution data and the relative incidence of
histological types of STS.
Extremity lesions were staged according to the
MTS staging system, 1980.
5 The pathological re-
ports were reviewed and assigned a grade (high or
low) according to the work of Trojani et al.
6 This
method uses tumour differentiation, mitosis count
and tumour necrosis to provide an estimation of
grade. The surgical technique used and results of
investigation were correlated to allow estimation of
surgical stage. Patients with a minimum follow-up
of 5 years were identi® ed and methods of primary
management were collated. The 5-year survival
rates were analysed by primary treatment employed,
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by commonest histological type and by disease stage
(MTS Surgical Staging System, 1980). Patterns of
treatment failure were then investigated. Finally,
time to ® rst recurrence was analysed.
Results
Incidence of STS (Mersey 1975± 1985)
The above criteria were satis® ed by 544 patients;
309 males and 235 females, giving a male to female
ratio for the study of 1.32:1. The mean age of the
309 males was 53.9 years (range 1 month to 97
years). The mean age of the 253 females was 55.5
years (range 9 days to 88 years). The age/sex distri-
bution of STS in the Mersey Region (1975± 85) is
shown in Fig. 1. The number of new cases of STS
diagnosed annually is shown in Fig. 2. The mean
number of new cases occurring annually was 49.5
(range 37± 66) for all sites. Age-speci® c annual inci-
dence for STS is shown in Fig. 3. The peak inci-
dence of STS for both sexes occurs in the over 85
years age group, in which STS are twice as common
in males as in females. It should be noted that, for
both sexes, STS become progressively more com-
mon after 45 years of age.
The sites of occurrence of STS for the 544 pa-
tients in the study are shown in Table 1. A group of
274 patients with limb girdle and extremity STS
were identi® ed. The mean number of new STS
occurring annually in the lower and upper limbs was
18.2 (range 12± 34) and 6.7 (range 3± 13), respect-
ively. The mean number of extremity lesions occur-
ring annually was thus 24.9 (range 18± 41). Further
age/sex distribution data for extremity lesions were
calculated (Table 2) giving a male to female ratio
of 1.3:1 and a lower limb to upper limb ratio of
2.7:1.
The relative incidence of histological types of STS
of the extremities is presented in Table 3.
Fig. 1. Age and sex distribution of soft tissue sarcomas (Mersey Region 1975± 1985).
Fig. 2. Incidence of soft tissue sarcomas (Mersey Region 1975± 1985).Incidence and results of extremity lesion treatment 91
Fig. 3. Age-speci® c annual incidence of soft tissue sarcomas (Mersey Region 1975± 1985).
Table 1. Sites of occurrence of STS in the Mersey Region (1975± 1985)
Head and neck Trunk Retroperitoneum Upper Lower
(%) (%) (%) extremity*(%) extremity**(%)
46 (8.5) 145 (26.7) 79 (14.5) 74 (13.6) 200 (36.8)
*Shoulder/arm, 44 (8.1); forearm/wrist, 23(4.2); hand, 7 (1.2).
**Gluteal/thigh, 121 (22.2); knee/leg, 56 (10.3); ankle/foot, 23 (4.2).
Table 2. Age/sex distributionÐ of extremity STS, Mersey Region (1975±
1985)
No. of patients Mean age in years (range)
Male
Upper limb 40 50.1 (8± 76)
Lower limb 115 53.0 (9± 92)
Female
Upper limb 34 60.8 (8± 97)
Lower limb 85 57.2 (8± 89)
Table 3. Relative incidence of histological types of extremity STS
Lower (%) Upper (%)
(1) Fibrosarcoma 56 (20.4) 22 (8.0)
(2) Unclassi® ed 35 (12.8) 16 (5.8)
(3) Malignant ® brous histiocytoma 12 (4.4) 5 (1.8)
(4) Liposarcomas (unclassi® ed) 11 (4.0) 5 (1.8)
(5) Synovial sarcomas 8 (2.9) 6 (2.2)
(6) Rhabdomyosarcoma 12 (4.4) 1 (0.4)
(7) Spindle cell sarcoma 19 (3.6) 2 (0.7)
(8) Myxoid liposarcoma 11 (4.0) 0 (0.00)
(10) Giant cell sarcoma 6 (2.2) 2 (0.7)
Others 29 (10.5) 14 (5.2)
Results of Extremity Soft Tissue Sarcomas Treatment
The 274 extremity lesions were staged according to
the MTS Staging System, 1980
5 (Table 4). The
methods of primary management were collated
(Table 5). Nine patients were not treated due to
patient refusal, disease being unresectable or patient
being deemed medically un® t for treatment. Sixty-
eight (24.8%) patients underwent excisional bi-
opsy 6 adjuvant therapy. No incisional biopsies were
performed and, for the purpose of this study, wide
excision was de® ned as tumour removal with a
surrounding cuff of normal tissue greater than 2 cm
in all directions. It was not possible to de® ne accu-92 M. J. Jane & P. J. Hughes
Table 4. Surgical stage of 274 extremity lesions
Stage Number Percentage of total
IA 42 15.3
IB 60 21.9
IIA 52 19.0
IIB 92 33.6
IIIA 11 4.0
IIIB 17 6.2
operatively after 2± 3 weeks delay to allow wound
healing. Typically, radiotherapy was administered by
megavoltage technique using parallel opposed ® elds,
vital structures being protected by wedging the X-ray
® eld. Palliative radiotherapy in one or two fractions
was used in some patients, but most patients received
their therapeutic external beam irradiation to the
primary site, drain tracks and lymph nodes; 35±
65 Gy over 3± 6 weeks being the usual regime.
Chemotherapy was used as part of the primary
management in certain situations, which included
patients presenting with disseminated disease and
patients with advanced primaries not amenable to
surgical treatment and who did not respond to
radiotherapy. A variety of chemotherapeutic regimes
rately oncological surgical margins (intralesional,
marginal, wide or radical) from examination of the
surgical records and pathological reports.
Radiotherapy, when utilised, was given post-
Table 5. In¯ uence of primary treatment method on survival in 233 patients with extremity
STS followed up for greater than 5 years (Mersey 1975± 1985)
Number Number surviving
Treatment Treated 5 years %
No treatment 9 0 0
(un® t or refusing)
Excision biopsy 19 2 10.5
Excision biopsy
1 radiotherapy 20 5 25.0
Excision biopsy
1 chemotherapy 9 0 0
Excision biopsy 1 radiotherapy 1
chemotherapy 11 3 27.3
Wide local excision 98 56 57.1
Wide local excision 1 radiotherapy 35 17 48.6
Wide local excision 1
chemotherapy 3 1 33.3
Wide local excision 1 radiotherapy
1 chemotherapy 7 1 14.3
Amputation 18 9 50.0
Amputation 1 radiotherapy 1 0 0
Amputation 1 chemotherapy 2 0 0
Amputation 1 radiotherapy
1 chemotherapy 1 1 100.0
Table 6. Five-year survival rates of the 10 most common histological types of STS (201
patients)
No. surviving
No. of cases 5 years %
Fibrosarcoma 68 28 41.2
Unclassi® ed 51 9 17.6
Malignant ® brous histiocytoma 12 11 91.7
Liposarcomas (unclassi® ed) 14 6 42.9
Synovial cell sarcomas 13 6 46.2
Rhabdomyosarcoma 10 3 30
Spindle cell sarcoma 10 3 30
Leiomyosarcoma 8 3 37.5
Myxoid liposarcoma 8 5 62.7
Giant cell sarcoma 7 3 42.9Incidence and results of extremity lesion treatment 93
Table 7. Treatment results of 233 cases of extremity STS classi® ed according to stage of disease
Stage Number of cases Number surviving 5 years %
Stage I (IA 1 IB) 84 48 57.1
Stage II (IIA 1 IIB) 128 47 36.7
Stage III (IIIA 1 IIIB) 21 0 0
Table 8. Patterns of failure by histological type for 233 patients with extremity STS
Local
Local Distant failure Local
failure metastasis and Lymph Recurrence
No. alone alone metastasis nodes (%)
Fibrosarcoma 68 15 9 19 6 50.0
Unclassi® ed 51 11 6 11 3 43.1
Malignant ® brous histiocytoma 12 1 3 3 ± 33.3
Liposarcomas (unclassi® ed) 14 2 3 3 ± 35.7
Synovial cell sarcomas 13 4 2 5 1 69.2
Rhabdomyosarcoma 10 4 ± 4 1 80.0
Spindle cell sarcoma 10 3 ± 6 2 90.0
Leiomyosarcoma 8 2 3 3 2 62.5
Myxoid liposarcoma 8 3 1 1 ± 50.0
Giant cell sarcoma 7 3 1 1 ± 57.1
Overall for all 233 STS 55 31 65 18
(23.6%) (13.3%) (27.9%) (7.7%)
were used during the study period including adri-
amycin plus DTIC and methotrexate, vincristine,
adriamycin and cyclophosphamide, and high-dose
methotrexate alone and with vincristine. These were
all administered i.v., no use was made of hyperther-
mic isolation perfusion. No patients received adju-
vant chemotherapy.
The 5-year survival rates for 233 patients with a
minimum follow up of 5 years were analysed by
method of treatment employed (Table 5). The over-
all 5-year survival rate for the series was 40.8%. The
amputation rate was 9.4%. The 5-year survival rate
of patients treated by wide local excision 6 adjuvant
was 52.4%. This compares with the 5-year survival
rate of 45.5% for those patients treated by ampu-
tation 6 adjuvant therapy. Limb-sparing surgery did
not appear to prejudice long-term survival. Excision
biopsy alone is to be condemned as a method of
treatment as this is associated with only 10.5%
5-year survival.
The 5-year survival rates occurring in the 10 most
common histological types were calculated (Table
6). The results of treatment by disease stage (MTS
Surgical Staging System, 1980) were also investi-
gated (Table 7).
The patterns of failure of 233 patients were then
studied. Lymph node involvement occurred in 18
(6.6%) patients. Local failure occurred in 120
(43.8%). Distant metastases without local recur-
rence occurred in 31 (11.3%). Treatment failure by
histological type is shown (Table 8).
Finally, in this study, time to ® rst local recurrence
in patients was analysed. Seventy percent of tu-
mours that recurred locally did so by the ® rst year,
95% recurred by 3 years, and only two ® rst local
recurrences occurred more than 5 years from pri-
mary surgery.
Discussion
In this study the incidence of STS in Mersey Region
was investigated. At 2.0 per 100 000 (2.36/100 000
for males and 1.68 per 100 000 for females) this rate
is identical to the rate reported by the US Depart-
ment of Health in 1976.
1 The incidence of STS
increases steadily with age after 34 years, and is
higher in males, such that in the greater than 85-
year age group STS are twice as common amongst
men. This increase with age may be due to environ-
mental exposure to carcinogens, cumulative degen-
erative genetic damage and immunosuppression of
old age. Other studies have shown an increased
occurrence of those tumours amongst men.
7 In this
study males out-numbered females by 1.32 to 1.
The reason for this is unknown but may be due to
occupational exposure to carcinogens.
When compared with previous studies,
8± 11 the
relative incidence of histological types of STS show
some marked disparities. Unclassi® ed tumours are
far more common in this series (19.7% of cases
compared with 10.5%, a mean of four series). This
may be a re¯ ection of the lack of expertise in pathol-
ogy, as appropriate biopsy technique and histologi-
cal experience can enable more tumours to be
categorised. Synovial sarcomas and rhabdomyosar-
comas occurred with a reduced frequency when
compared to other studies. Fibrosarcomas com-
prised the largest group of tumours, being 23.3% of94 M. J. Jane & P. J. Hughes
the total. Malignant ® brous histiocytoma was diag-
nosed rather infrequently (6.6%). This may again be
related to pathological inexperience, as many tu-
mours formally regarded as ® brosarcomas are now
classi® ed as malignant ® brous histiocytomas. Elec-
tron microscopy and the use of special stains have
enabled greater categorisation of STS. This is
clearly a reason for the establishment of STS Path-
ology Units.
The distribution of STS was largely as reported in
previous studies.
8± 11 Retroperitoneal tumours were
more common than expected (14.5% of cases com-
pared with a mean of 11.6% in four other studies),
and lower limb tumours were less common than
expected (36.8% compared with a mean of 41.8%).
Thus, data from the Mersey study appears con-
sistent with previous investigations, and the few
results appearing outside the expected range appear
to be due to inexperience in histological diagnosis.
Extremity STS
In this study, lower limb lesions outnumbered upper
limb lesions by 2.7 to 1. This probably re¯ ects the
greater soft tissue bulk of the lower limb. Females
developing tumours were older than their male
counterparts; females with upper limb tumours
were, on average, 4.2 years older than their male
patients. Anatomically, STS were distributed such
that 44.2% of extremity lesions occurred in the
buttock/thigh region, knee and lower leg tumours
comprised 20.4% of lesions, and shoulder and arm
tumours comprised 16% of all lesions. Soft tissue
sarcomas at other more distal sites were relatively
rare. This overall distribution compares well with
previous studies.
Examination of histological types in extremity le-
sions con® rmed the preponderance of ® brosarcomas
and unclassi® ed STS together with the diminished
incidence of malignant ® brous histiocytomas. It was
noted that synovial sarcomas are increased in inci-
dence (2.8% for all sites, 5.1% for extremity lesions)
and leiomyosarcomas are less common in the ex-
tremities (7.2% of all sites; 4.0% for extremity le-
sions).
The 274 extremity lesions were staged according
to the Enniking MTS surgical staging system, 1980.
This form of retrospective cross-correlating between
surgical technique, pathological examination, pre-
operative examination and investigation is well
known to be inaccurate. Better surgical techniques
along oncogenic lines will allow better future evalu-
ation of data; however, within these constraints the
distribution of extremity lesions was as follows:
stage Ia 15.3%, Ib 21.9%, IIa 19.0%, IIb 33.6%,
IIIa 4.0% and IIIb 6.2%. This compares well to the
work of Simon and Enniking who examined a large
series of extremity STS.
12
There are several interesting observations to be
made upon the management of extremity STS in
the Mersey Region. Firstly, the amputation rate at
9.9% is low and compares favourably with contem-
porary series.
3,13 Excision biopsy alone was per-
formed in 22 cases, 23 patients received excision
biopsy and radiotherapy. There is abundant evi-
dence to show that excision biopsy alone is an
inadequate form of treatment. There appears to be
no logical explanation why so many patients treated
by excision biopsy were not subsequently given ra-
diotherapy. Surgeons may not have referred these
patients or, conversely, radiotherapists may not have
considered these tumours radio-responsive. Again,
in the case of wide local excision, 41 patients had
supplementary radiotherapy whilst 115 patients had
surgery alone. If the results are examined the 5-year
survival rate for wide local excision alone was 57.1%
compared with 48.6% for wide local excision plus
radiotherapy. This may imply that radiotherapy was
reserved for patients with larger tumours resulting in
poorer prognosis. The 5-year survival rate for
Mersey extremity STS (40.8%) appears low when
contemporary series of patients treated by limb-
sparing surgery are attaining 61% (range, 47.6±
67.0%) 5-year survival rates.
14± 16 Solutions to
explain this poor outcome cannot be derived from
these data due to the lack of comparable groupings.
The present study reveals that 5-year survival rate
following wide local excision 6 adjuvant therapy is
52.4%, and that following amputation 6 adjuvant
therapy it is 45.5%. The present study therefore
reveals that limb-sparing surgery, as performed in
the Mersey Region, whilst not attaining the results
of other centres,
17 does not appear to compromise
long-term survival when compared to amputation.
Five-year survival by histopathological type and
stage of disease at presentation was also reviewed.
Better differentiated tumours were noted to have
better 5-year survival rates. The unclassi® ed group,
as would be expected, had the poorest prognosis,
and the 5-year survival rate was only 17.6%. Five-
year survival by disease stage was as follows: stage I
51.7%, stage II 36.7%, stage III 0%. Contemporary
studies show 90± 95% 5-year survival rates for stage
I lesions, 45% survival for stage II lesions and 5%
survival for stage III lesions.
14,15 Most of these con-
temporary series have patients with similar stage
disease but differ in that aggressive radiotherapy was
used either pre-or post-operatively.
The patterns of failure of patients treated for STS
reveal some interesting features. Patients developing
distant metastases alone amounted to 13.3%, but
most published series show isolated distant metasta-
sis is the commonest mode of treatment failure. The
present study reveals local failure 6 distant metasta-
sis occurred in 51.9% of patients. Contemporary
series showed this mode of failure occurs in only
16.0%. The relationship between local control and
subsequent distant metastasis and tumour-related
mortality is exceedingly complex.
18 The marked rate
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causally to distant metastasis. It does, however, sug-
gest inadequate treatment in the management of
local disease.
Lymph node metastasis occurred in 18 patients
(7.6%) treated during the study period; this agrees
well with the 5.8% lymph node involvement rate
reported by Ariel.
19 Metastasis to lymph nodes oc-
curred with increasing frequency in patients with
leiomyosarcomas, synovial cell sarcomas and
® brosarcomas, in comparison with other series.
The local recurrence rate for excision biopsy
alone was found to be 81.8%; this compares to a
local recurrence rate of 47.8% when local excision is
supplemented with radiotherapy. The addition of
radiotherapy to wide local excision decreases the
local recurrence rate from 35.7 to 29.3%. Local
recurrence rate for patients treated by amputation-
was 18.5%; this compares favourably with reported
local failure rates of 15.8% for patients treated by
amputation.
12,20,21 Unfortunately there was no way
of categorising amputees as being marginal, wide or
radical. De® nite conclusions about what constitutes
adequate local treatment cannot be drawn from this
work due to the likely heterogeneous nature of both
the patient groups and treatment protocols. Patients
who develop local recurrence are clearly at increased
risk of developing distant metastasis and tumour-
related mortality. There was under-use of radiother-
apy in the Merseyside Region during the study
period, this cannot explain the poor survival rates
reported here, but may provide an explanation for
the very high and undesirable rates of local recur-
rence. This strengthens the argument for a com-
bined modality treatment approach to the
management of STS.
Histological type also appears to in¯ uence local
recurrence. Spindle cell sarcomas, rhabdomyosarco-
mas and synovial cell sarcomas had high local recur-
rence rates at 90.0, 80.0 and 69.2%, respectively.
Wide variation in these rates have previously been
noted.
22 Local recurrence rates for ® brosarcomas,
liposarcomas and leiomyosarcomas were 50.0, 35.7
and 62.5%, respectively. It is well known that cer-
tain histological types show a predeliction to local
recurrence. However all these rates are high when
compared with other studies.
12,23 Clearly the local
control was inadequate with regard to all histologi-
cal types. The time to local recurrence was in accord
with the work of Cantin et al.
24 and revealed that of
these tumours destined to recur 95% had done so
by 5 years.
In summary, this investigation has shown the
Mersey Region population is at average risk of de-
veloping STS. The rarity of these lesions mean that
in the UK, a given surgeon with an average sized
practice will only see an STS every 1± 2 years. This
inexperience has lead to suboptimal treatment of
extremity lesions in terms of both local recurrence
and 5-year survival. This inexperience is also mani-
fest in pathological assessment, as there were clear
weaknesses in classi® cation of the lesions during the
study period. This work has further highlighted the
importance of establishing multidisciplinary teams
involving surgeons, radiologists, radiotherapists and
oncologists to plan and organise multimodality ther-
apy for STS.
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